Dec. 4 (UPI) -- Gilead Sciences announced a nationwide recall of 55,000 vials of its COVID-19 treatment drug remdesivir due to the "presence of glass particulates."
The U.S.-based biopharmaceutical firm said the two recalled lots of remdesivir, which is also known by the brand name Veklury, were limited to the United States, and no reports of adverse events had been reported in connection with the recalled vials.